CD274 and renal cell carcinoma: This includes monoclonal antibody-based treatments with anti-PD-L1 ICP inhibitors and therefore the relevant ratio between membranous and secreted PD-L1 splice variants, which can be observed with high frequency in renal cell carcinoma [25].